Today: 7 February 2026
Subscribe
Browse Category

LSE:VOD.L News 6 January 2026 - 31 January 2026

Vodafone share price today: VOD edges up near a 52-week high as Centrica deal and buyback keep focus on Feb 5 update

Vodafone share price today: VOD edges up near a 52-week high as Centrica deal and buyback keep focus on Feb 5 update

Vodafone shares rose 0.1% to 106.45 pence in early London trading, near a 52-week high, after announcing a four-year UK enterprise deal with Centrica and a new subsea fibre project in Greece. The company repurchased 2.52 million shares on Jan. 27. Investors await Vodafone’s third-quarter trading update and interim dividend schedule on Feb. 5.
29 January 2026
·
Vodafone share price edges up after fresh buyback disclosure — here’s what traders watch next

Vodafone share price edges up after fresh buyback disclosure — here’s what traders watch next

Vodafone shares rose 0.1% to 102.05 pence in early London trading after the company bought back nearly 2.85 million shares at an average price of 102.02 pence. The shares, acquired from Merrill Lynch International, will be held in treasury. Vodafone closed Monday at 102.00 pence, up 1.19% from Friday. The company’s next trading update is scheduled for Feb. 5.
20 January 2026
·
Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone shares fell 0.4% to 98.3 pence by 0932 GMT in London, after a 2.6% drop Tuesday, despite another buyback announcement. The company repurchased over 5.2 million shares on Jan. 13, adding to its treasury stock. Investors are awaiting Vodafone’s trading update on Feb. 5 for further direction. UBS maintained its “sell” rating but raised the target price to 82 pence.
14 January 2026
··

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop